Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 18/20 | 0.76 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.54 |
| ▸ | RAC1 | P63000 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765226 | 0.87 | TERT (1.00) | TERTDOT1L | |
| SCHEMBL7250482 | 0.86 | TERT (0.72) | TERTDOT1LRAC1 | |
| SCHEMBL6765978 | 0.85 | TERT (1.00) | TERTDOT1L | |
| SCHEMBL7255812 | 0.84 | TERT (0.70) | TERTDOT1LRAC1 | |
| SCHEMBL7256127 | 0.83 | TERT (0.69) | TERTDOT1LRAC1 | |
| SCHEMBL6345682 | 0.83 | TERT (0.54) | TERTDOT1LRAC1 | |
| SCHEMBL5630421 | 0.82 | TERT (0.88) | TERTDOT1L | |
| SCHEMBL6765942 | 0.81 | TERT (0.86) | TERTDOT1L | |
| SCHEMBL5631618 | 0.80 | TERT (0.84) | TERTDOT1L | |
| SCHEMBL4074842 | 0.79 | TERT (0.91) | TERTDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179816-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2007-02-20 | — | — | US | disclosed |
| US-20050070575-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-03-31 | — | — | US | disclosed |
| US-6858608-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20030078263-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA SA (FR) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078263-A1 | Chemical derivatives and their application as antitelomerase agents | TERT, TERF2, DUT | TERT 1/4885DOT1L 376/4885RAC1 1454/4885 |
| US-20050070575-A1 | Chemical derivatives and their application as antitelomerase agents | TERT, TERF2, DUT | TERT 1/4885DOT1L 376/4885RAC1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.